Home › Uterine Cancer › Maryland › Baltimore
Uterine Cancer clinical trials in Baltimore, MD
4 studies for Uterine Cancer are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Baltimore
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Baltimore
- Research Site, Baltimore
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- The John Hopkins Hospital, Baltimore
Image-Guided Gynecologic Brachytherapy
Recruiting
- The SKCCC at Johns Hopkins, Baltimore
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Austin, TX5 studies
- Miami, FL5 studies
- Orlando, FL4 studies
- Chicago, IL4 studies
- West Palm Beach, FL4 studies
- Providence, RI4 studies
- Pittsburgh, PA4 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Pancreatic Cancer31 studies
- Colorectal Cancer31 studies
- Metastatic Cancer28 studies
- Obesity26 studies
- Bladder Cancer24 studies
- Heart Failure24 studies
- Ovarian Cancer22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.